Weekly Ophthalmic Newsletter

1. Study: Novel Algorithm Predicts AMD Progression with 94% Accuracy

Researchers at 美国杜克大学 have developed a computer program that can predict with 94% accuracy whether an individual's age-related macular degeneration (AMD) will deteriorate within a year.

The deep learning algorithm, featured in an article within JAMA Ophthalmology, evaluates comprehensive eye scans to forecast the progression of the common eye condition to a more advanced stage called geographic atrophy (GA).

Click here to read the full news.

2. Medical Breakthrough: World’s First Whole-eye and Partial Face Transplant

In a groundbreaking medical feat, a surgical team comprising more than 140 clinicians, including surgeons, nurses, and various healthcare professionals from NYU Langone Health , has successfully conducted the world's first whole-eye and partial face transplantation on a 46-year-old man.

In a 21-hour procedure, the surgical team achieved a medical milestone by successfully transplanting the entire left eye and part of the face from a donor to the patient. This marks the first instance of a human whole-eye transplant combined with a partial facial transplant.

Click here to read the full news.

3. Biological Engineers Validate Alternative Treatments for AMD

A Utah State University professor, along with her team, has discovered a potential solution for addressing age-related macular degeneration, a primary cause of vision impairment among the elderly.

Elizabeth Vargis , an associate professor of biological engineering, recently published a paper in the Molecular Vision Journal on November 3rd. Vargis' research reveals that the regulation of retinal pigment epithelial (RPE) cell growth, a crucial cell type within the eye, can elucidate the connection between RPE cell detachment and the formation of blood vessels.

Click here to read the full news.

4. VSY Biotechnology Develops a Novel Anti-VEGF Agent for the Treatment of AMD

VSY Biotechnology is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD).

“We have been developing a new anti-VEGF agent, named Varliciment, which would be as effective as brolicizumab, but have a better safety profile. The drug has shown very promising efficacy than other anti-VEGF agents on the market with the lowest possibility of immunogenicity,” said researchers from the R&D Department at VSY Biotechnology.

Click here to read the full news.

5. Kodiak Revives Drug Development Program for Diabetic Retinopathy

Kodiak Sciences is resuming the development of its drug after a 5-mg dose of tarcocimab tedromer met the primary endpoint in one-year data from the GLOW trial in non-proliferative diabetic retinopathy. The company ended its drug development in July as it failed to deliver significant vision improvement for patients with DME.

Click here to read the full news.

If you want to stay updated with the latest news via e-mail,?click here ?to subscribe.